Cure My Disease

Don't miss your cure!

 Log in / Sign up

New buprenorphine start aims to sidestep fentanyl withdrawal

NCT ID NCT06379984

Recruiting now Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests a new method called ROLDI (rapid outpatient low-dose initiation) for starting buprenorphine in people with opioid use disorder who use fentanyl. The goal is to see if this approach can begin treatment without causing severe withdrawal symptoms. Participants will be randomly assigned to either the standard start or the new ROLDI method in a monitored research unit. The trial focuses on safety, feasibility, and whether the method is acceptable to patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
buprenorphine
What this could lead to
If successful, this approach could make it easier and safer for people using fentanyl to start buprenorphine treatment without severe withdrawal.
What could go wrong
This is a small early-phase trial (60 people) testing feasibility, not effectiveness. The new method may still cause withdrawal or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID USE DISORDER

Contacts and locations

Locations

  • University of Pennsylvania Center for Studies of Addiction

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.